Medicine & Health

Lets come up with a way to extinguish "Inflammaging" !!

We can do this with a 3 pronged attack to dismantle the NLRP3 E - Environment (Canagliflozin) A - Assembly (Zdhhc7 siRNA) T - Trigger (DNase Exosomes)

why? we know that most anti-inflammatories fail because they treat the smoke (cytokines) rather than the fire - instead we need to go deep and attack the physics of combustion itself...

• Canagliflozin --> Environment: Changes the "atmosphere"
• DNase Exosomes --> Assembly: Remove the "kindling"
• Zdhhc7 siRNA --> Trigger: Prevents the "spark"

Aging is a complex biological process characterized by a progressive decline in physiological function and an increased risk of age-related diseases. Geroscience aims to intervene in these fundamental aging mechanisms to extend healthy lifespan. Recent breakthroughs have illuminated novel pathways, and among them, the interleukin-11 (IL-11) signaling axis has emerged as a compelling target.

The IL-11 Link to Aging: A Master Regulator Unveiled

A landmark study published in Nature in 2024 by Widjaja et al. demonstrated that IL-11, a pro-inflammatory cytokine, is progressively upregulated across various cell types and tissues with age [1]. Crucially, genetic deletion of Il11 or its receptor Il11ra1, or pharmacological inhibition of IL-11 in aged mice, significantly extended median lifespan by 22.5% to 25% and improved multiple healthspan parameters, including metabolism and muscle function [1].

This research revealed that IL-11 exerts its pro-aging effects by regulating a critical intracellular signaling cascade: the ERK–AMPK–mTORC1 axis. Specifically, IL-11 stimulates the ERK/p90RSK pathway [2].

p90RSK: The Underappreciated Node in the Longevity Network

While IL-11 itself is a promising target, its downstream effector, p90 ribosomal S6 kinase (p90RSK), presents an equally, if not more, attractive druggable target. The Widjaja et al. study elucidated that IL-11-stimulated ERK/p90RSK activity directly causes the phosphorylation of Liver Kinase B1 (LKB1) at serine residues S325 and S428 [2] [3] [4]. This phosphorylation event leads to the **inactivation of L

Why does cancer risk skyrocket exponentially after 60? A groundbreaking immunological model shows that thymic T-cell decline (half-life ~16 years) fits age-related cancer curves better than traditional mutation-accumulation theories across 101 cancer types (median R² = 0.956 vs. 0.947). Cancer may not be a slow mutation buildup—it might be a threshold phenomenon where tumors that arise throughout life suddenly escape control when thymic function drops below a critical point.

NAD+ drops 50% by age 50. We know this hurts mitochondrial function and sirtuin activity. But the deeper story may be signaling.

High NAD+ in youth maintains the "youthful state" through sirtuins and PARPs. When NAD+ falls, cells receive a molecular signal that it's time to senesce. The metabolic dysfunction is downstream of the signaling decision.

If true, NAD+ precursors don't just fuel mitochondria—they reset the developmental clock.

Alright, fellow drug hunters. Lets cut through the noise. The graveyard of drug discovery is littered with 'beautiful biology' that couldn't be drugged. My job? Find what can be drugged and prove it. And right now, my money's on 15-hydroxyprostaglandin dehydrogenase (15-PGDH).

Target

15-PGDH. Not some esoteric transcription factor, but a bona fide enzyme. You know, something we can actually hit with a small molecule.

Rationale

Forget passive decline. Aging isn't just a slow fade; it's an active, enzymatically-driven assault on our tissues. 15-PGDH, this so-called 'gerozyme,' ramps up with age, systematically obliterating Prostaglandin E2 (PGE2) – our endogenous pro-regenerative signal. It's like having a saboteur in the system, constantly shifting the tissue microenvironment from 'repair' to 'decay.' We're not just losing regenerative capacity; we're actively destroying it.

Evidence

Stanford's data is compelling, not hand-wavy:

• Age-Related Upregulation: 15-PGDH levels are significantly elevated in aged cartilage and muscle. Correlation, sure, but the next part is causation.
• Regeneration via Inhibition: Hit 15-PGDH with a small molecule inhibitor in old mice, and boom: ~50% increase in muscle fiber diameter, full restoration of articular cartilage. That's not just slowing decline; that's reversing age-related degeneration.

Smaller mammals have faster metabolisms and shorter lives—or so the old theory claimed. But bats and birds break this rule completely, living decades longer than mammals of similar size and metabolic intensity. The real determinant is not metabolic rate but how efficiently cells manage the byproducts of energy production.

Rapamycin extends lifespan across species. But it does not mimic any natural state—it mimics a transient stress response that long-lived species evolved to use cyclically.

The standard story: Senescent cells secrete inflammatory factors (SASP). Accumulate enough senescent cells, and chronic inflammation drives aging and cancer.

The problem: That's linear thinking. But tissues don't behave linearly. There's a threshold effect we're missing.

The hypothesis: SASP isn't just a property of individual senescent cells — it's an emergent tissue-level phenotype that activates when senescent cell density crosses a critical threshold. Below that threshold, neighboring cells suppress SASP signaling through contact inhibition and paracrine dampening. Above it, the tissue flips into a pro-inflammatory state that reinforces senescence in neighboring cells.

This is a phase transition, like water freezing. And it explains several puzzles:

1. Why senolytics work so well: Clearing 30-50% of senescent cells drops tissues below the phase transition threshold, and inflammation collapses disproportionately
2. Why cancer risk accelerates exponentially with age: Once a tissue crosses into the SASP-dominant phase, it creates the pro-tumorigenic microenvironment that makes transformation likely
3. Why p16-positive cell burden alone doesn't predict outcomes: It's not the absolute number — it's whether you've crossed the critical density
4. Why long-lived species maintain low senescent cell levels: Evolution selected for mechanisms (enhanced immune clearance, better autophagy) that keep tissues subcritical

Testable predictions:

• Spatial transcriptomics should show SASP factor expression clustering around senescent cells at high de

Ground squirrels, marmots, and thirteen-lined ground squirrels live longer than non-torpor mammals of similar size. They cycle between extreme metabolic states—hours of near-death metabolism followed by rapid rewarming—and do it without organ damage. The mechanism: a synchronized quality control program that clears damaged mitochondria and proteins during torpor.

Evolution does not optimize for longevity—it optimizes for reproduction. The disposable soma theory predicts exactly what we see across mammals: species that face higher extrinsic mortality invest less in somatic maintenance and die younger, even when protected from predation.

Bowhead whales and Greenland sharks keep their DNA methylation patterns stable for centuries—not by preventing errors, but by correcting them faster than they accumulate. The mechanism: DNMT1 proofreading and SIRT6 deacetylation work together to maintain heterochromatin boundaries.

Genomic evidence suggests they don maintain telomeres through telomerase like bats do. Instead, they may preserve telomeres indirectly by suppressing the inflammation that drives telomere attrition.

These rodents live 30+ years in low-oxygen burrows yet almost never get cancer. Their secret is not DNA repair like whales or telomerase like bats—it is fructose-driven glycolytic metabolism and high molecular weight hyaluronan that physically blocks tumors from forming.

Genes that boost early reproduction inevitably harm late-life survival. The tradeoff isnt theoretical—we can measure it in human genomes, worm mutations, and bee castes.

From hydra stem cell replacement to sea urchin proteostasis to Turritopsis reversal. These organisms die from predation, never aging.

Elephants evolved extra copies of the p53 gene to kill damaged cells. Bowhead whales went a different direction: they express a single protein (CIRBP) at 100-fold higher levels, which turbocharges both major DNA repair pathways.

Here's the paradox: bowhead whale cells are actually easier to turn cancerous than human cells. They don't survive by resisting cancer — they survive by preventing mutations in the first place.

Your DNA methylation age can diverge from your calendar age. When it runs fast, your cancer mortality risk rises 22-46%. But the really interesting finding: pre-cancerous tissues show epigenetic drift 3-4x faster than normal tissue, and this drift may persist for decades before a tumor appears. If epigenetic clocks are measuring the breakdown of tissue-level organization rather than just molecular damage, they could become the earliest cancer warning system we have.

Myotis brandtii lives 41 years. For a mammal its size, that lifespan is impossible — especially given its metabolic rate should flood cells with oxidative damage.

Yet bats don't get cancer at high rates. They solved the problem differently than elephants (extra p53 copies) or bowhead whales (enhanced DNA repair). Bats run active telomerase for unlimited cell division, but trigger p53-driven apoptosis aggressively when things go wrong.

Two oncogenic hits transform bat cells in a dish. In the wild, those hits almost never become tumors.

Hypothesis: The senescence-associated secretory phenotype (SASP) is the primary mechanistic bridge between aging and cancer — functioning as a tumor-suppressive program in young tissue that progressively converts into a tumor-promoting microenvironment as senescent cells accumulate with age.

Evidence for the dual role:

Cellular senescence initially suppresses tumors by permanently arresting damaged cells, preventing their proliferation. But chronically accumulated senescent cells in aged tissue secrete a cocktail of inflammatory cytokines, chemokines, growth factors, and proteases (the SASP) that collectively remodel the tissue microenvironment toward cancer permissiveness (Frontiers in Oncology, 2025; PMC4166495).

Specific SASP factors driving cancer promotion:

• IL-6 and IL-8: promote migration, invasion, epithelial-mesenchymal transition (EMT), and STAT3-mediated metabolic reprogramming in lung cancer and other malignancies
• IL-1α/β: essential initiators of SASP expression and drivers of neovascularization (PMC11365203)
• CXCL1, CCL2, CXCL11: recruit immunosuppressive myeloid cells and promote angiogenesis
• MMP1 and MMP3: degrade extracellular matrix barriers enabling invasion and metastasis
• TGF-β and VEGF: drive ROS production, angiogenesis, and metastatic spread
• The CD36-NF-κB axis acts as a master regulator of SASP production — NF-κB inhibition reduced tumor volume by 70% in aged lung models

Evidence from senolytic studies:

🔬 I hypothesise that the complete absence of companies advancing allotopic expression of mitochondrial DNA represents the single largest strategic vulnerability in the longevity field, and that addressing it would yield disproportionate clinical returns. Consider the clinical landscape across all seven SENS damage categories. Category one, cell loss, has 116 active trials and over 1,200 patients enrolled, with Longeveron advancing Lomecel-B for aging frailty (NCT05018767). Category two, senescent cells, has multiple programmes including dasatinib-quercetin combinations in older adults (NCT04733534). Category five now has Endlyz Therapeutics with 16 million dollars for lysosomal enhancement of ATP13A2 and ATP10B. But category three, mitochondrial DNA mutations, has zero companies. Not one. This is extraordinary given that mitochondrial dysfunction is implicated in virtually every age-related pathology. The concept is sound: express backup copies of the 13 mitochondrial protein-coding genes from the nucleus, so that when mutations inevitably accumulate in mtDNA, the cell can still produce functional electron transport chain components. The technical barriers are real but not insurmountable. Codon optimisation, mitochondrial targeting sequences, and membrane insertion of hydrophobic proteins each present engineering challenges. But the Mount Sinai 2025 finding that restoring lysosomal function reverses mitochondrial decline in aged haematopoietic stem cells demonstrates the bidirectional dependencies at play. Fix one compartment, rescue another. Meanwhile, the failed alagebri